Euclidean Capital LLC
Long book
$392.3M
Q1 2026
Positions
10
Top-10 weight
100%
concentration
Last quarter
+10.1%
SPY +14.8%
Turnover
17%
of book per quarter
Strategy in plain words
auto-generated from filingsEuclidean Capital LLC is a wealth-management firm allocating client money, specialised in healthcare (100% of the long book), running a $392.3M US long book across 10 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: VANGUARD FTSE ALL-WORLD EX-U, VANGUARD VALUE ETF, ISHARES MSCI INDIA ETF, ORIC PHARMACEUTICALS INC, FOGHORN THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 0.8pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+3.1%
Q2 2024
+6.3%
Q3 2024
-1.3%
Q4 2024
-3.9%
Q1 2025
+11.5%
Q2 2025
+2.5%
Q3 2025
+1.9%
Q4 2025
+2.8%
Q1 2026
+10.1%
Sector allocation
Healthcare 100%
Long book by quarter
What does Euclidean Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 989.4K | $12.5M | 3.2% | Held |
| FHTX FOGHORN THERAPEUTICS INC | Healthcare | 1.6M | $7.5M | 1.9% | Held |
| PMVP PMV PHARMACEUTICALS INC | Healthcare | 2.6M | $3.3M | 0.8% | Held |
| ALEC ALECTOR INC | Healthcare | 1.3M | $2.8M | 0.7% | Held |
| SRZN SURROZEN INC | Healthcare | 87.7K | $2.6M | 0.7% | Held |
| TNYA TENAYA THERAPEUTICS INC | Healthcare | 1.0M | $703K | 0.2% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 10 | $392.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 12 | $369.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 11 | $238.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 11 | $305.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 11 | $266.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 11 | $736.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 12 | $906.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 11 | $795.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 13 | $780.0M | canonical | SEC ↗ |